Robert Maykut

Omalizumab for asthma in adults and children

Suppressive effect of low-level laser therapy on tracheal hyperresponsiveness and lung inflammation in rat subjected to intestinal ischemia and reperfusion

Update on optimal use of omalizumab in management of asthma

IgE and mast cells in allergic disease

Asthma

Local and remote tissue injury upon intestinal ischemia and reperfusion depends on the TLR/MyD88 signaling pathway

New and Anticipated Therapies for Severe Asthma

In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid

mRNA transcript therapy

Sleep in children with asthma: results of the PIAMA study

Mechanisms and applications of the anti-inflammatory effects of photobiomodulation

Lung microvascular permeability and neutrophil recruitment are differently regulated by nitric oxide in a rat model of intestinal ischemia–reperfusion

IgE, mast cells, basophils, and eosinophils

Mast cell and eosinophil surface receptors as targets for anti-allergic therapy

Exploring the Effects of Omalizumab in Allergic Asthma

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

Urticaria and Angioedema

Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision

Fungal allergy in asthma–state of the art and research needs

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

Oxidative Stress: An Essential Factor in the Pathogenesis of Gastrointestinal Mucosal Diseases

Oxidative damage of SP-D abolishes control of eosinophil extracellular DNA trap formation

Uncontrolled Asthma Among Children: Impairment in Social Functioning and Sleep

The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthma

Treatment of chronic autoimmune urticaria with omalizumab

Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients

Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: Real-life data

Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

Addition of Omalizumab Improved Functional Health Status in Patients With Impaired Quality of Life Associated With Moderate-Severe Persistent Allergic Asthma

Addition of Omalizumab Reduces School Absenteeism in Children with Moderate-Severe Persistent Asthma

Pathophysiology and Implications for Treatment of Acute Respiratory Distress Syndrome

Addition of Omalizumab Improves Quality of Life in Moderate-Severe Asthmatics Receiving Fluticasone 500 μg/Salmeterol 50 μg

Effect of Omalizumab on Asthma Control and Quality of Life in Patients with Moderate-Severe Persistent IgE-Mediated Asthma and Allergy to House Dust Mite

Omalizumab Reduced Need for Steroid Bursts and Improved Treatment Effectiveness in Asthmatics on Inhaled Salmeterol and Fluticasone Combination Therapy

ADDITION OF OMALIZUMAB IMPROVES LUNG FUNCTION AND TREATMENT EFFECTIVENESS IN PATIENTS WITH MODERATE-SEVERE PERSISTENT ALLERGIC ASTHMA INADEQUATELY CONTROLLED WITH INHALED STEROIDS AND LONG-ACTING BETA-AGONISTS